Agretti Patrizia, De Marco Giuseppina, Collecchi Paola, Chiovato Luca, Vitti Paolo, Pinchera Aldo, Tonacchera Massimo
Medicina del Lavoro, Università di Pisa, Pisa, Italy.
Eur J Biochem. 2003 Sep;270(18):3839-47. doi: 10.1046/j.1432-1033.2003.03778.x.
Activating mutations of the thyroid-stimulating hormone receptor (TSHr) have been identified as a cause of toxic adenomas. Germline-inactivating TSHr mutations have been described as a cause of congenital hypothyroidism. The effects of combining activating and inactivating mutations within a single receptor was studied. The double mutant T477I/P639S contained an activating TSHr mutation (P639S) together with an inactivating one (T477I). The other one (I486M/P639S) contained two activating mutations. Constructs were expressed in COS-7 cells and basal and TSH-stimulated cyclic AMP (cAMP) accumulation and inositol phosphate (IP) production were determined. The expression at the cell surface was studied both with binding and fluorescence-activated cell scanning analysis. Our results show that the effect of combining the two activating mutations is an increase in the constitutive activity only for the cAMP pathway and not for the IP pathway suggesting that different mutations result in receptor conformations with different relative abilities to couple to Gs-alpha or Gq-alpha. Surprisingly the double mutant containing the T477I behaves as an activating receptor with constitutive activity both for the cAMP and IP pathways. These data show that an inactive form of the TSHr which is trapped inside a cell after transfection is able to gain the membrane surface when combined with an activated form of the receptor.
促甲状腺激素受体(TSHr)的激活突变已被确认为毒性腺瘤的一个病因。种系失活的TSHr突变已被描述为先天性甲状腺功能减退的一个病因。研究了在单个受体内同时存在激活突变和失活突变的影响。双突变体T477I/P639S包含一个激活的TSHr突变(P639S)以及一个失活突变(T477I)。另一个突变体(I486M/P639S)包含两个激活突变。构建体在COS-7细胞中表达,并测定基础状态下以及促甲状腺激素刺激后的环磷酸腺苷(cAMP)积累和肌醇磷酸(IP)生成情况。通过结合分析和荧光激活细胞扫描分析研究了细胞表面的表达情况。我们的结果表明,两个激活突变相结合的效应是仅对cAMP途径的组成性活性增加,而对IP途径无此作用,这表明不同的突变导致受体构象与Gs-α或Gq-α偶联的相对能力不同。令人惊讶的是,含有T477I的双突变体表现为对cAMP和IP途径均具有组成性活性的激活受体。这些数据表明,转染后被困在细胞内的无活性形式的TSHr与受体的激活形式结合时能够到达膜表面。